Global Continuous Glucose Monitoring Systems Market Size Study, by Component (Sensors, Transmitters & Receivers), by Demography (Child Population, Adult Population), by End User (Hospitals & Clinics, Home Healthcare, Others), and Regional Forecasts 2022-2

Global Continuous Glucose Monitoring Systems Market Size Study, by Component (Sensors, Transmitters & Receivers), by Demography (Child Population, Adult Population), by End User (Hospitals & Clinics, Home Healthcare, Others), and Regional Forecasts 2022-2032

The global continuous glucose monitoring systems (CGMS) market was valued at approximately USD 6,626.6 million in 2021 and is expected to grow to USD 31,708.2 million by 2032, with a CAGR of 17.0% from 2022 to 2032. Continuous glucose monitoring systems (CGMs) are pivotal medical devices that provide real-time glucose level monitoring for patients, enabling better management of diabetes. These systems consist of sensors, transmitters, and display devices, offering continuous data to patients and healthcare providers. The burgeoning demand for CGMs is driven by the rising incidence of diabetes and the increasing preference for home care applications.

The market dynamics are influenced by the growing innovations in medical devices for CGM manufacturing, creating numerous opportunities. Notably, developments such as the world's first multi-sensor non-invasive CGM by GlucoRx and Cardiff University in 2022 exemplify the technological advancements propelling market growth. Additionally, the increasing geriatric population and prevalence of diabetes further fuel market expansion. However, high costs and regulatory challenges in developing regions pose constraints. Yet, the anticipated rise in healthcare investments and advancements in R&D in emerging economies are projected to offer significant growth opportunities.

Regionally, North America dominated the market in 2021, attributed to the presence of key players, high prevalence of diabetes, and well-established healthcare infrastructure. The Asia-Pacific region is expected to witness the highest growth rate due to the increasing geriatric population, advancements in healthcare infrastructure, and rising awareness about CGMs.

Major market players included in this report are:
• A. Menarini Diagnostics S.r.l
• Abbott Laboratories
• DexCom, Inc.
• F. Hoffman-La Roche Ltd
• GlySens Incorporated
• Johnson & Johnson
• Medtronic plc
• Novo Nordisk A/S
• Senseonics
• Ypsomed AG

The detailed segments and sub-segments of the market are explained below:
By Component:
• Sensors
• Transmitters & Receivers
By Demography:
• Child Population (≤14 years)
• Adult Population (>14 years)
By End User:
• Hospitals & Clinics
• Home Healthcare
• Others
Common content for ‘Report Description’
By Region: North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
Latin America
• Brazil
• Mexico
Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.